Navigation Links
Alzheimer's Drug Discovery Foundation Funds American Life Science Pharmaceuticals, Inc to Move Novel Therapeutic Towards Clinic

NEW YORK, May 24 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it is providing a grant of $248,000 to American Life Science Pharmaceuticals, Inc. (ALSP) to allow for manufacture of its lead drug candidate to be used in preclinical toxicology testing in preparation for entering Phase I clinical trials early in 2011.

ALSP is developing new methods to effectively treat neurodegenerative disease with an initial focus on Alzheimer's disease (AD). ALSP has identified a new class of drugs that prevent memory deficit and pathology in animal models of AD. "Our proprietary lead compound, AB-007, has previously been evaluated for a different indication in human clinical trials and shown to be safe and well tolerated," said company CEO, Michael D. Pierschbacher, PhD. "Our goal is to conduct clinical trials on AB-007 to confirm as soon as possible the observed preclinical efficacy for treatment of AD."

ALSP was recently awarded a National Institute on Aging (NIA) contract to pay for all Investigational New Drug (IND)-enabling toxicology and pharmacology studies. "This ADDF grant combined with the NIA contract makes it possible for us to move this promising Alzheimer's drug through toxicology testing toward the clinic at maximum speed," said Greg Hook, PhD, JD, an ALSP founder. ALSP is currently launching aggressive efforts to raise Series A financing.

ALSP's technology comes out of Vivian Hook, PhD's laboratory at the UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences. Dr. Hook discovered that a novel target enzyme may be responsible for the production of the majority of the beta amyloid peptide in sporadic Alzheimer's disease.  

"The ultimate test for any investigational treatment is in human trials," said the ADDF's executive director, Howard Fillit, MD. "This ADDF grant accelerates AB-007 into clinical testing."

For more information about the ADDF or to speak with Dr. Fillit, please contact Diana Shineman, PhD at 212-901-8007 or  For information about ALSP, Inc. or to speak with Dr. Michael Pierschbacher, call 858-273-3900 or e-mail

About the Alzheimer's Drug Discovery Foundation (

The ADDF is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. Since 1998, the ADDF has granted more than $40 million to fund over 295 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 15 countries. 

About American Life Science Pharmaceuticals, Inc. (

ALSP is a privately held company located in San Diego, CA. The company and its world class team is passionate about finding a drug that prevents the devastation that is Alzheimer's disease.  We believe that our lead candidate, AB-007, represents a first-in-class drug that has an excellent chance to meet that challenge. ALSP is poised to enter the crucible of the clinic to put its approach to the test.

SOURCE Alzheimer's Drug Discovery Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
2. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
3. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
4. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
5. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
6. Five Clinical Studies to Receive $2.5 Million Under Foundations 2007 Clinical Discovery Program
7. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
8. FASgen Announces New Discovery for Treatment of Stroke
9. Nobel Prize-Winning Discovery
10. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
11. FASgen Announces a New Discovery in Obesity Research
Post Your Comments:
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/22/2017)... Md. , Sept. 22, 2017  As the ... Republican Senators Bill Cassidy (R-LA) and ... Information notes that the medical device industry is in ... medical device tax, the 2.3% excise tax on medical ... But they also want covered patients, increased visits and ...
(Date:9/19/2017)... medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound energy ... ... Jim Bertolina, PhD ... Tom Tefft ... executive Josh Stopek , PhD, who has led R&D and business development teams at ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... While it’s often important to take certain medications during the night, finding them ... a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX to provide ... need to turn on a light when taking medication during the night, allowing the ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical ... the primary prevention of cardiovascular diseases during the 15th Annual Women’s Health ...
(Date:10/13/2017)... BASKING RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... second annual Holly Day Market. Featuring a collection of specialty vendors and unique items ... myriad of personalized and quality-focused health and wellness services offered by the VNA. ...
(Date:10/13/2017)... ... , ... Talented host, actor Rob Lowe, is introducing a ... episode of "Success Files," which is an award-winning educational program broadcasted on PBS ... in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve in ...
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
Breaking Medicine News(10 mins):